Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 20;4(1):e000181.
doi: 10.1136/bmjgast-2017-000181. eCollection 2017.

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience

Peter Nguyen  1   2 , Philip Vutien  1 , Joseph Hoang  1 , Sam Trinh  1 , An Le  1 , Lee Ann Yasukawa  3 , Susan Weber  3 , Linda Henry  4 , Mindie H Nguyen  1
Affiliations

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience

Peter Nguyen et al. BMJ Open Gastroenterol. .

Abstract

Background: Cure rates for chronic hepatitis C have improved dramatically with direct-acting antivirals (DAAs), but treatment barriers remain. We aimed to compare treatment initiation rates and barriers across both interferon-based and DAA-based eras.

Methods: We conducted a retrospective cohort study of all patients with chronic hepatitis C seen at an academic hepatology clinic from 1999 to 2016. Patients were identified to have chronic hepatitis C by the International Classification of Diseases, Ninth Revision codes, and the diagnosis was validated by chart review. Patients were excluded if they did not have at least one visit in hepatology clinic, were under 18 years old or had prior treatment with DAA therapy. Patients were placed in the DAA group if they were seen after 1 January 2014 and had not yet achieved virological cure with prior treatment. All others were considered in the interferon group.

Results: 3202 patients were included (interferon era: n=2688; DAA era: n=514). Despite higher rates of decompensated cirrhosis and medical comorbidities in the DAA era, treatment and sustained virological response rates increased significantly when compared with the interferon era (76.7% vs 22.3%, P<0.001; 88.8% vs 55%, P<0.001, respectively). Lack of follow-up remained a significant reason for non-treatment in both groups (DAA era=24% and interferon era=45%). An additional 8% of patients in the DAA era were not treated due to insurance or issues with cost. In the DAA era, African-Americans, compared with Caucasians, had significantly lower odds of being treated (OR=0.37, P=0.02).

Conclusions: Despite higher rates of medical comorbidities in the DAA era, considerable treatment challenges remain including cost, loss to follow-up and ethnic disparities.

Keywords: chronic viral hepatitis; health service research; hepatitis c.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MHN: grant/research support: Bristol Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals and National Cancer Institute; advisory board/consultant: Anylam Pharmaceutical, Gilead Sciences, Dynax Laboratories and Intercept Pharmaceutical.

Figures

Figure 1
Figure 1
Study flow diagram. A total of 3202 patients were seen in subspecialty hepatology clinic: 2688 patients in the IFN era and 514 in the DAA era. CHC, chronic hepatitis C; DAA, direct-acting antiviral; ICD-9, International Classification of Diseases, Ninth Revision; IFN, interferon; SVR, sustained virological  response.
Figure 2
Figure 2
Treatment effectiveness by era. Treatment effectiveness by time period. Of all patients seen in a subspecialty hepatology clinic, 22.3% (white bar) of patients in the IFN era were treated and 12.3% achieved SVR. Seventy-seven per cent (black bar) of patients were treated and 68.5% achieved SVR in the DAA era. CHC, chronic hepatitis C; DAA, direct-acting antiviral; IFN, interferon; SVR, sustained virological  response.
Figure 3
Figure 3
Reasons for lack of treatment in the DAA era. In the DAA era, the most common reasons for lack of treatment were the management of other life-limiting comorbidities (42%) and issues with follow up (24%). DAA, direct-acting antiviral.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Butt AA, Justice AC, Skanderson M, et al. . Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385–9. doi:10.1136/gut.2006.099150 - DOI - PMC - PubMed
    1. Feillant M, Jézéquel C, Lison H, et al. . Chronic hepatitis C: treat or wait? A prospective study on reasons for treatment or nontreatment in the era of first-generation protease inhibitors. Eur J Gastroenterol Hepatol 2016;28:164–72. doi:10.1097/MEG.0000000000000506 - DOI - PubMed
    1. Ghany MG, Strader DB, Thomas DL, et al. . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74. doi:10.1002/hep.22759 - DOI - PMC - PubMed
    1. Kramer JR, Kanwal F, Richardson P, et al. . Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012;56:320–5. doi:10.1016/j.jhep.2011.05.032 - DOI - PubMed
    1. Vutien P, Hoang J, Brooks L, et al. . Racial disparities in treatment rates for chronic hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States. Medicine 2016;95:e3719 doi:10.1097/MD.0000000000003719 - DOI - PMC - PubMed

LinkOut - more resources